{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-024098","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.364031+00:00","generated_at":"2026-06-25T23:28:41.617251+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024","bullets":["Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.","Cash and equivalents $118.5M as of March 31, 2022; expected to fund operations into mid-2024.","Phase 1 ADVANCED-1 trial of TARA-002 for NMIBC first patient dosed in March 2022.","FDA preliminary guidance received for TARA-002 in lymphatic malformations; Phase 2 trial planning underway.","U.S. patent issued for IV Choline Chloride composition with term expiring in 2041."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-024098","json":"https://secwatch.observer/filing/0001213900-22-024098.json","markdown":"https://secwatch.observer/filing/0001213900-22-024098.md","text":"https://secwatch.observer/filing/0001213900-22-024098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/0001213900-22-024098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/ea159335-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:28:41.617251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}